Limited Distribution Deals Announced
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
April 11, 2023
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
If you have you ever tried to explain all the nuances behind the host of decisions to launch a new specialty therapy through limited distribution, then
Walgreens has tripled down on acquisitions over the past year to the tune of several Billion $$$ in a quest to totally remodel the 122
In the old days (before the internet) the importance of a news item was often expressed in how many column inches the item was generating
We missed one! The FDA recently (back on January 27th) approved a new ORAL therapy, Orserdu (elacestrant) from Stemline Therapeutics, Inc., indicated for postmenopausal women
Remicade is one of the cornerstone therapies in the market racking up billions in annual sales. But J&J-Janssen didn’t appreciate the approvals of four biosimilars starting
Today we spotlight an article that details the leading healthcare services companies. While the information may be old news for many of you, it may be
Last week the FDA approved a new oral solution therapy, Daybue (trofinetide) from Acadia Pharmaceuticals Inc., for the treatment of Rett syndrome in adult and
The number of biosimilars launching in 2023 will spike as legal challenges around patent infringement are finally expiring. That will only exacerbate the problem of biosim
The article below should be a learning moment for the specialty pharmacy industry. It is all about going digital…. but it does not get lost in techno
